Abstract We here provide definitive evidence that ginsenosideRg1, the pharmacologically active component of ginseng, is a functional ligand of the glucocorticoid receptor (GR) as determined by fluorescence polarization assay. Rg1 increased the phosphorylation of GR, phosphatidylinositol-3 kinase (PI3K), Akt/PKB and endothelial nitric oxide synthase (eNOS) leading to increase nitric oxide (NO) production in human umbilical vein endothelial cell. Rg1-induced eNOS phosphorylation and NO production were significantly reduced by RU486, LY294,002, or SH-6. Also, knockdown of GR completely eliminated the Rg1-induced NO production. This study revealed that Rg1 can indeed serve as an agonist ligand for GR and the activated GR can induce rapid NO production from eNOS via the non-transcriptional PI3K/Akt pathway.
Introduction
Panax Ginseng C.A. Meyer and its related species have been used as health tonics for centuries in Chinese medication. Ginsenosides, the pharmacologically active components found in ginseng, are triterpenoid saponins that are broadly classified into 20(S)-protopanaxatriols (PPT) and 20(S)-protopanaxadiols (PPD) [1] . Ginsenoside-Rg1, a PPT (see Fig. 5A ), has been demonstrated to trigger transcriptional activation of a glucocorticoid responsive element (GRE)-containing reporter gene, suggesting that Rg1 can activate the glucocorticoid receptor (GR) [2] . Recently, glucocorticoids (GCs) have been reported to activate the phosphatidylinositol-3 kinase (PI3K)/Akt pathway after binding to the GR [3] . PI3K/Akt pathway is a crucial regulator in cell proliferation, cell-cycle progression, and a mediator of cellular survival [4] . The activated PI3K/Akt pathway leads to phosphorylation of endothelial nitric oxide synthase (eNOS) and increases the production of nitric oxide (NO) [5] . NO-related endothelial proliferation and angiogenesis were shown to be part of the activities of Rg1 [6] . To elucidate the role of the GR in Rg1-induced NO production, we have examined the state of GR activation and the downstream activation pathways of PI3K, Akt/protein kinase B (PKB) and eNOS in human umbilical vein endothelial cells (HUVEC). In addition, a molecular docking study of Rg1 to the GR was also performed. This work can provide molecular basis for the diverse activities of ginseng.
Materials and methods

Materials
Culture medium M199 and endothelial cell growth supplement (ECGS) were purchased from Sigma. Foetal bovine serum (FBS) was from Gibco. RU486, LY294,002 and ICI182,780 were from Sigma. SH-6 and L L-NMMA was from Calbiochem and Cayman, respectively. Anti-GRa was from Santa Cruz Biotechnology. Anti-phospho-GR (Ser211) and anti-phospho-PI3 kinase p85 were from Cell Signaling. Anti-PI3 kinase p85, anti-Akt1/PKBa, anti-phospho-Akt1/PKBa (Ser473), anti-eNOS/NOSIII and anti-phospho-eNOS (Ser1177) were from Upstate. Anti-b-actin was from Sigma. Alexa Fluor 488 anti-rabbit IgG (Molecular Probe) and anti-rabbit IgG HRP (Zymed) were used for immunocytochemistry and immunoblotting, respectively. Small interfering RNA (siRNA) was custom-designed and purchased from Dharmacon (M-003424-02).
HUVEC culture conditions
HUVEC (Clonetics) were grown in M199 supplemented with 20% FBS, 20 lg/ml ECGS, 90 U/ml Heparin (Sigma), 1% penicillin-streptomycin-neomycin (PSN, Gibco) and 50 ng/ml amphotericin B (Sigma). Cultures were maintained at 37°C in humidified CO 2 incubator (5% CO 2 ). HUVEC were used at passages 2-8.
NO production assay
HUVEC were seeded in a 96-well plate at 2 · 10 4 cells/well. Rg1 of various concentrations was prepared in serum-free medium. The concentrations of NO 2.4. siRNA transfection siRNA duplex oligo targeting GR mRNA was transfected with siLenfect (Invitrogen) at 5 nM into HUVEC. Concentrations of NO produced after 30 min treatment of Rg1 (150 nM) or Dex (500 nM) were estimated according to the method mentioned above.
Western blot analysis
Total cellular protein was obtained by lysing cells with lysis buffer (Novagen) supplemented with phosphatase and protease inhibitor cocktail (Merck). SDS-PAGE resolved protein bands were transferred to nitrocellulose membranes (Amersham). After blocking with 5% skimmed milk, the membrane was incubated with primary antibodies (1:1000 dilution) for 3 h, followed by horseradish peroxidase-conjugated IgG (1:2000 dilution). Target proteins were visualized with enhanced chemiluminescence reagents (BioRad). Semi-quantifications were performed with densitometric analysis by Metamorph software.
GR competitive ligand-binding assays
Commercially available GR competitive binding assay was used (Invitrogen). Serial 2-fold dilution of Dex (1 lM to 0.9 nM) and Rg1 (2 lM to 1.8 nM) were competed with Fluormone, a proprietary fluorescent GC ligand provided in the kit, for binding to the human GR. The fluorescence polarization was measured by a PTI Fluorescence Lifetime Scanning Spectrometer. Negative (without any ligand; 0% competition) and positive (1 mM Dex; 100% competition) controls delimited the fluorescence polarization range. IC 50 is defined as the concentration of a test compound that causes a half-maximum shift in polarization. The equilibrium dissociation constant (K d ) is the concentration of the competing ligand occupying half of the binding sites in the absence of the tracer ligand. The equilibrium binding curves were fitted with a two-state one-site competition model.
Translocation of phosphorylated GR
Images of the phosphorylated GR in HUVEC were collected with a Zeiss LSM-510 multi-tracking laser scanning confocal microscope (Carl Zeiss SAS, Frankfurt, Germany) for translocation study. HU-VEC (5 · 10 4 cells) seeded on 13-mm diameter coverslips were fixed with 4% paraformaldehyde and incubated in anti-phospho-GR (Ser211) antibody with 0.1% Triton X-100 (Chemicon) and 2% normal goat serum (Gibco) for 3 h, followed by incubating in Alexa Fluor 488 in dark for 2 h. The coverslips were mounted with DAKO mounting medium. Images were captured (63·) within 72 h. For each treatment, 50 cells were analyzed and the ratio of nucleus/cytoplasm fluorescence intensity (R N/C ) was calculated.
Statistical analysis
Numerical results were analyzed using one-way ANOVA with Duncan post hoc test. Values shown are means of at least N = 3 experiments with ±S.D. Differences were considered statistically significant at a value of P 6 0.05. Data significantly different from control was marked with * in the figures.
Results
Rg1 increases NO production
The production of NO by HUVEC was increased by treatment with Rg1 over a 15-fold dose range (Fig. 1A) . Based on this finding, HUVEC were challenged with 150 nM Rg1 and the time profile of NO production was monitored for 60 min. An immediate linear rise in the total NO level was detected followed by a plateau after 10 min (Fig. 1B) . Using Western blotting, the phosphorylation of eNOS at Ser1177 in response to Rg1 treatment was detected. An approximately 2.5-fold increase in the phosphorylated form of eNOS was detected as early as 10 min and this trend continued to increase up to 60 min after the exposure of HUVEC to 150 nM Rg1 ( Fig. 2A) . This provides direct evidence that Rg1 rapidly activates eNOS in HUVEC.
Activation of eNOS via the GR and PI3K/Akt pathway
The upstream phosphorylation of the GR (Ser211), PI3K p85-subunit and Akt/PKB (Ser473) were also found to increase during the 60 min duration of exposure to 150 nM Rg1 as determined by Western blotting (Fig. 2B) . The phosphorylation of GR was peaked at 10 min and dropped back to the base level at 60 min. The phosphorylation of PI3K and Akt/PKB, however, were more sustainable after reaching their maximum at 15 and 30 min, respectively. These results indicated a sequential activation from the GR to the PI3K/Akt pathway. The Rg1-induced eNOS phosphorylation at Ser1177 was abolished by the GR antagonist RU486; PI3K inhibitor LY294,002; and Akt/PKB inhibitor SH-6 (Fig. 3) . Also, the production of NO was diminished to the baseline level in the presence of RU486 (Fig. 4) . However, the Rg1-induced NO production was unaffected by an estrogen receptor (ER) antagonist ICI182,780 (10 lM) (Fig. 4) ,. Moreover, knockdown of the GR by siRNA completely eliminated the Rg1-induced NO production (Fig. 4) . concentrations in serum-free culture media. Total NO production was calculated from a calibration curve generated from standards provided by the manufacturer and normalized by the protein content of the corresponding wells (N = 3; ±S.D.). All data were significantly different from control at a value of P 6 0.05.
Rg1 binding to the GR
A competitive ligand-binding assay was performed to study the specific binding of Rg1 to the GR using a proprietary fluorescent GC ligand (Fluormone)-recombinant human GR complex. Displacement of Fluormone from the GR-Fluormone complex by Rg1 results in a decrease in fluorescence polarization. The shift in polarization is used to determine the relative specific affinity of that ligand for the GR. The competitive ligand-binding assay indicated that Rg1 is indeed a ligand of the GR (Fig. 5A) (Fig. 5A) . We speculated that Rg1 may bind to the same site as of Dex that is the ligand-binding domain (LBD) of the GR. Using the crystal structure of GR-LBD and Dex, we were able to show by modeling the docking of Rg1 to the ligand-binding site in place of Dex (Fig. 5B) . Although the attached glucosyl rings on Rg1 cause steric bumps, this ginsenoside molecule still marginally fits into the hydrophobic cavity around the LBD even without significant conformational rearrangement of the protein.
Translocation of the phosphorylated GR
Ligand-activated steroid receptors can elicit both rapid nontranscriptional and genomic effects. The genomic effects of Rg1 binding to the GR were assessed by monitoring the translocation of the GR-ligand complexes from cytoplasm to nucleus. Exposure of HUVEC to Rg1 (150 nM) and Dex (5 lM) resulted in almost 2-and 5-fold increase in the ratio of nuclear/cytoplasmic fluorescent intensity (R N/C ), respectively (Fig. 6 ). This indicated that both Rg1 and Dex not only enhance the phosphorylation of the GR, but also induce the translocation of the phosphorylated GR into the nucleus. Furthermore, the translocation due to Rg1 was inhibited by the GR-antagonist RU486 (Fig. 6C) . That means the blockade of the GR by RU486 not only affects the non-transcriptional pathways of Rg1, but also the transcriptional ones.
Discussion
GCs are a class of stress-induced steroid hormones that exert their actions through activation of GR, a member of the nuclear receptor (NR) superfamily [7] . Increasing evidence shows that activation of the GR triggers non-transcriptional pathways that lead to NO production and vasodilation within minutes [8] . Clinically, for patients with myocardial infarction [9, 10] and ischaemic stroke [11] , high doses of corticosteroids or Dex were given to activate eNOS and subsequently induce vasodilation to transiently decrease blood pressure and systemic vascular resistance accompanied by an increase in coronary and cerebral blood flow [9] [10] [11] . The current findings provide direct evidence that the Rg1 exerts GC-like effects by acting as a functional ligand of the GR to induce non-transcriptional effect leading to NO production through PI3K/ Akt pathway in endothelial cells. The eNOS is one of the isoforms of the NOS family responsible for NO production in HUVEC [12] . NO is an important transcellular signaling molecule contributing to anti-tumor [13] , anti-microbial [14] , anti-inflammatory [15] , anti-oxidative [16] and immunosuppressive activity of macrophages [14] [15] [16] . Owing to its vasodilating property, NO plays an important role in cardiovascular protection [17] . The increased phosphorylation of eNOS (Ser1177) and NO production in HUVEC after exposure to Rg1 indicated that part of the physiological effects of Rg1 could be mediated by NO.
Western blot analysis indicated that Rg1 can rapidly activate GR, PI3K and Akt/PKB. The PI3K/Akt pathway is known as one of the candidates that are capable of activating eNOS directly [18] . In the present study, phosphorylation of eNOS and NO production were abolished by the inhibitors/antagonists: RU486 [19] , LY294,002 [20] , or SH-6 [21] , whilst ICI182,780 had no effect. Since RU486 can act as a progesterone receptor (PR) antagonist [22] , siRNA targeting GR was used in HU-VEC in order to preclude the involvement of other NRs in the Rg1 induction pathway. Our results showed GR knockdown completely abolished the Rg1-induced NO production. These data confirmed the predominant involvement of GR and the PI3K/Akt pathway in the Rg1-induction pathway, while the ER and PR were not involved.
The activated PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP 2 ), resulting in phosphatidylinositol-3,4,5-triphosphate (PIP 3 ) that subsequently binds to Akt/protein kinase B (Akt/PKB) [23] . Activation of PI3K/Akt pathway is a key step for diverse biological effects, including cell proliferation, growth, and survival [24, 25] . Therefore, cellular activities brought about by the Rg1-activated PI3K/Akt pathway via the specific binding with the GR warrant further investigations. The present results showed that Rg1 is able to trigger the rapid non-transcriptional effects through the GR fi PI3K fi Akt/PKB fi eNOS.
Upon ligand binding, the GR dissociates from hsp90-based chaperones, translocates from cytoplasm to nucleus and regulates gene expression by complexing with the GRE [26, 27] . We demonstrated that the translocation of the phospho-GR in HUVEC was enhanced by Rg1 and Dex by immunofluorescence study. The competitive binding assay and the molecular docking study support the view that Rg1 can exert its genomic effects by binding to the LBD of the GR.
In view of the steroidal skeleton of the ginsenosides and the similarity of the side effects of ginseng overdosing to those of the corticosteroids or estrogens, the hypothesis that ginsenosides can act as steroid hormones is sustainable. In the present study, we have clearly demonstrated that Rg1 can act as an agonist for the GR, leading to transcriptional and non-transcriptional effects. However, Rg1 represents only one of the major ginsenosides in ginseng, the study of the combinatorial interactions between ginsenosides and the diverse NRs and their effects will be an important step towards unraveling the mystery of ginseng.
